Header Logo

Connection

JIUN-KAE JACK LEE to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Aged, 80 and over.
JIUN-KAE JACK LEE
Connection Strength
0.315
Aged, 80 and over
  1. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett. 2006 Jul 28; 239(1):136-43.
    View in: PubMed
    Score: 0.016
  2. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995 Oct; 1(10):1103-10.
    View in: PubMed
    Score: 0.008
  3. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
    View in: PubMed
    Score: 0.008
  4. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015 Apr; 10(4):682-90.
    View in: PubMed
    Score: 0.008
  5. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
    View in: PubMed
    Score: 0.007
  6. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84.
    View in: PubMed
    Score: 0.007
  7. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87.
    View in: PubMed
    Score: 0.007
  8. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21.
    View in: PubMed
    Score: 0.007
  9. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54.
    View in: PubMed
    Score: 0.007
  10. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
    View in: PubMed
    Score: 0.007
  11. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol. 2013 Oct; 24(10):2534-2542.
    View in: PubMed
    Score: 0.007
  12. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
    View in: PubMed
    Score: 0.007
  13. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.
    View in: PubMed
    Score: 0.007
  14. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
    View in: PubMed
    Score: 0.007
  15. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
    View in: PubMed
    Score: 0.007
  16. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84.
    View in: PubMed
    Score: 0.007
  17. Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev Res (Phila). 2012 Jun; 5(6):801-9.
    View in: PubMed
    Score: 0.006
  18. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32.
    View in: PubMed
    Score: 0.006
  19. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40.
    View in: PubMed
    Score: 0.006
  20. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82.
    View in: PubMed
    Score: 0.006
  21. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May 01; 118(9):2454-65.
    View in: PubMed
    Score: 0.006
  22. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769.
    View in: PubMed
    Score: 0.006
  23. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.006
  24. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85.
    View in: PubMed
    Score: 0.006
  25. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011 Apr 01; 17(7):2035-43.
    View in: PubMed
    Score: 0.006
  26. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29.
    View in: PubMed
    Score: 0.006
  27. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010 Jun 16; 102(12):859-65.
    View in: PubMed
    Score: 0.006
  28. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52.
    View in: PubMed
    Score: 0.005
  29. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res. 2010 Jan 01; 16(1):34-44.
    View in: PubMed
    Score: 0.005
  30. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604.
    View in: PubMed
    Score: 0.005
  31. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6014-22.
    View in: PubMed
    Score: 0.005
  32. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101.
    View in: PubMed
    Score: 0.005
  33. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008 Jan 20; 26(3):354-60.
    View in: PubMed
    Score: 0.005
  34. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007 Jun 01; 25(16):2164-70.
    View in: PubMed
    Score: 0.004
  35. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20; 25(15):1974-8.
    View in: PubMed
    Score: 0.004
  36. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006 Dec 01; 66(23):11194-206.
    View in: PubMed
    Score: 0.004
  37. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. Cancer Res. 2006 Sep 01; 66(17):8361-6.
    View in: PubMed
    Score: 0.004
  38. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006 Jun 01; 106(11):2428-36.
    View in: PubMed
    Score: 0.004
  39. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15; 12(10):3109-14.
    View in: PubMed
    Score: 0.004
  40. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.
    View in: PubMed
    Score: 0.004
  41. Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
    View in: PubMed
    Score: 0.004
  42. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005 Sep; 115(9):1561-7.
    View in: PubMed
    Score: 0.004
  43. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005 Feb 01; 23(4):759-65.
    View in: PubMed
    Score: 0.004
  44. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6119-25.
    View in: PubMed
    Score: 0.004
  45. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3230-7.
    View in: PubMed
    Score: 0.004
  46. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res. 2004 Mar 01; 10(5):1733-42.
    View in: PubMed
    Score: 0.004
  47. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.003
  48. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.003
  49. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18; 93(8):605-18.
    View in: PubMed
    Score: 0.003
  50. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol. 2000 Aug; 18(15):2798-804.
    View in: PubMed
    Score: 0.003
  51. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998 Aug; 124(2):203-10.
    View in: PubMed
    Score: 0.002
  52. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.
    View in: PubMed
    Score: 0.002
  53. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol. 1997 Dec; 151(6):1767-74.
    View in: PubMed
    Score: 0.002
  54. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997 Aug; 15(8):2826-31.
    View in: PubMed
    Score: 0.002
  55. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res. 1997 Jun; 3(6):875-80.
    View in: PubMed
    Score: 0.002
  56. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst. 1997 May 07; 89(9):624-9.
    View in: PubMed
    Score: 0.002
  57. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996 Dec; 2(12):2015-22.
    View in: PubMed
    Score: 0.002
  58. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 1995 Dec; 60(6):1563-70; discussion 1570-2.
    View in: PubMed
    Score: 0.002
  59. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol. 1995 Sep; 13(9):2361-8.
    View in: PubMed
    Score: 0.002
  60. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 1995 May 25; 332(21):1405-10.
    View in: PubMed
    Score: 0.002
  61. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994 Dec 01; 74(11):2908-17.
    View in: PubMed
    Score: 0.002
  62. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993 Jan 07; 328(1):15-20.
    View in: PubMed
    Score: 0.002
  63. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol. 1992 Oct; 10(10):1519-24.
    View in: PubMed
    Score: 0.002
  64. Exploring the influence of multiple variables on the relationship of age to quality of life in women with breast cancer. J Clin Epidemiol. 1992 May; 45(5):473-85.
    View in: PubMed
    Score: 0.002
  65. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res. 1992 Feb; 1(1):19-29.
    View in: PubMed
    Score: 0.002
  66. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer. 1991 Jun 15; 67(12):3131-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.